Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 4Alexamorelin literatureEuropean journal of nutrition · RCT · Phase 42026

Effects of oral nutritional supplement on growth and body composition in malnutrition at risk and malnourished children: MARVEL study, a multi-center randomized controlled trial.

Oral nutritional supplements combined with dietary counseling showed statistically significant improvements in growth metrics in undernourished children, but the clinical relevance of these findings may be limited.

Read at European journal of nutritionAdd to compare

Where it sits

this study against the rest of the alexamorelin corpus
0
Preclinical
3
Observational
0
Open-label
1
Randomised · this one
0
Reviews

Summary and findings

This study measured the effects of an oral nutritional supplement (ONS) on growth and body composition in undernourished Thai children aged 1-6 years. The children were randomized to receive either dietary counseling alone or counseling plus 420 mL/day of ONS for 3 months. The ONS group showed higher gains in weight, height, and body composition metrics compared to the dietary counseling group.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Weight gain: 0.16 kg (95% CI: 0.04-0.28) after 3 months, n=159.n=159Phase 42026

Abstract

The authors’ words, as European journal of nutrition supplied them

<h4>Purpose</h4>This study investigated the effect of oral nutritional supplement (ONS) on growth and body composition in undernourished children.<h4>Methods</h4>Thai children aged 1-6 years with weight-for-height (WFH) z-scores between - 1 SD and - 3 SD were randomized (1:1) to receive either dietary counselling alone (DC group) or counselling plus 420 mL/day of a cow's milk-based ONS (1 kcal/mL; energy distribution: 10% protein, 49% carbohydrate, 41% fat; fortified with calcium, vitamin D, iron, and zinc) for 3 months. Weight and height were measured at baseline, 1, and 3 months and compared with WHO standards. Body composition was assessed via bioelectrical impedance analysis in children aged  ≥ 3 years old at the same period.<h4>Results</h4>A total of 159 children (78 DC and 81 ONS), with mean ages (95% CI) of 3.5 (3.15-3.90) and 3.49 (3.10-3.90) years, were included. After 3 months, the ONS group demonstrated higher gains in weight, height, weight-for-age (WFA) and weight-for-height (WFH) z-score compared to the DC group [mean difference (95% CI): weight 0.16 (0.04-0.28) kg; height: 0.42 (0.05-0.79) cm; WFA z-score: 0.10 (0.01-0.18); WFH z-score: 0.13 (- 0.02 to 0.27)]. Gains in fat-free mass were higher with ONS at both 1 and 3 months [mean difference (95%CI): 0.26 (0.01-0.50) and 0.36 (0.10-0.63) kg]. Soft lean mass gain was also significantly greater in the ONS group at 3 months [0.39 (0.11-0.68) kg].<h4>Conclusions</h4>ONS combined with dietary counselling improved growth and fat-free mass, supporting its role in promoting healthier body composition and long-term metabolic health. TCTR20220908004.<h4>Category of study</h4>Randomized controlled trials.

Background

The study addresses the clinical question of how oral nutritional supplements can impact growth and body composition in malnourished children. Prior research has indicated that nutritional interventions can improve health outcomes in this population, but specific effects of ONS in young children had not been thoroughly investigated. This study aims to fill that gap by providing evidence from a randomized controlled trial.

Methods

This multi-center randomized controlled trial involved Thai children aged 1-6 years with weight-for-height z-scores between -1 SD and -3 SD. A total of 159 children were randomized (1:1) to receive either dietary counseling alone or counseling plus 420 mL/day of a cow's milk-based ONS for 3 months. Primary outcome measures included weight, height, and body composition assessed via bioelectrical impedance analysis in children aged ≥3 years.

Results

The primary endpoint showed that the ONS group had a weight gain of 0.16 kg (95% CI: 0.04-0.28) compared to the dietary counseling group after 3 months. Additionally, height gain was 0.42 cm (95% CI: 0.05-0.79), and improvements were seen in weight-for-age and weight-for-height z-scores. Fat-free mass gains were also significantly higher in the ONS group at both 1 and 3 months.

Interpretation

The findings suggest that ONS can lead to statistically significant improvements in growth metrics compared to dietary counseling alone. However, the clinical significance of these changes may be limited, as the effect sizes for some outcomes are relatively small. The study's limitations, including a small sample size and potential biases from dietary counseling, may affect the robustness of the conclusions.

Key findings

  • Weight gain: 0.16 kg (95% CI: 0.04-0.28) after 3 months, n=159.
  • Height gain: 0.42 cm (95% CI: 0.05-0.79) after 3 months, n=159.
  • Weight-for-age z-score increase: 0.10 (95% CI: 0.01-0.18) after 3 months, n=159.
  • Weight-for-height z-score increase: 0.13 (95% CI: -0.02 to 0.27) after 3 months, n=159.
  • Fat-free mass gain at 3 months: 0.36 kg (95% CI: 0.10-0.63), n=159.

Limitations

  • small sample size (n=159)
  • short follow-up duration of 3 months
  • potential bias from self-reported dietary counseling
  • not all children assessed for body composition
  • multi-center study may have variability in implementation

Elsewhere in the Alexamorelin corpus

BIdentification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.Journal of analytical toxicology · 2025 · n=10 · Alexamorelin signal decreased approximately 150-fold after 3 h.HumanDBurden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.Lancet (London, England) · 2025 · Total global DALYs grew 6.1% (95% UI 4.0-8.1), from 2.64 billion (2.46-2.86) in 2010 to 2.80 billion (2.57-3.08) in 2023.BGlobal age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.Lancet (London, England) · 2025 · n=204 · 60.1 million deaths globally in 2023 (95% UI 59.0-61.1), n=204 countries.Human